QUEST LABORATORIES Stock Price Today (NSE: QUESTLAB)
Fundamental Score
QUEST LABORATORIES Share Price — Live NSE/BSE Price, Fundamentals & Analysis
QUEST LABORATORIES share price today is ₹89.25, down 6.05% on NSE/BSE as of 31 July 2026. QUEST LABORATORIES (QUESTLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹146.99 (Cr). The 52-week high for QUESTLAB share price is ₹145.35 and the 52-week low is ₹84.00. At a P/E ratio of 9.79x, QUESTLAB is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 16.82% and a debt-to-equity ratio of 0.08.
QUEST LABORATORIES Share Price Chart — NSE/BSE Historical Performance
QUEST LABORATORIES share price chart: -4.80% return over the past month. 52-week high ₹145.35, 52-week low ₹84.00.
QUEST LABORATORIES — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹92.00 | ₹92.00 | ₹88.80 | ₹89.25 | 45.60K (Cr) | |
| ₹87.20 | ₹96.75 | ₹87.20 | ₹95.00 | 44.40K (Cr) | |
| ₹89.00 | ₹90.00 | ₹88.50 | ₹90.00 | 18.00K (Cr) | |
| ₹92.90 | ₹93.00 | ₹92.75 | ₹92.95 | 18.00K (Cr) | |
| ₹93.00 | ₹93.00 | ₹90.35 | ₹92.90 | 12.00K (Cr) | |
| ₹92.30 | ₹93.10 | ₹91.65 | ₹92.95 | 7.20K (Cr) | |
| ₹96.60 | ₹98.75 | ₹96.00 | ₹97.10 | 21.60K (Cr) | |
| ₹86.00 | ₹90.50 | ₹86.00 | ₹89.70 | 12.00K (Cr) | |
| ₹95.00 | ₹96.50 | ₹92.00 | ₹94.95 | 50.40K (Cr) | |
| ₹92.30 | ₹95.00 | ₹92.30 | ₹93.75 | 37.20K (Cr) |
QUEST LABORATORIES — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹92.30 | ₹98.75 | ₹86.00 | ₹89.25 | -3.30% | |
| ₹102.10 | ₹102.10 | ₹99.25 | ₹101.10 | -0.98% | |
| ₹140.00 | ₹143.90 | ₹103.90 | ₹116.10 | -17.07% | |
| ₹131.90 | ₹145.35 | ₹129.05 | ₹145.35 | +10.20% | |
| ₹105.00 | ₹110.70 | ₹102.95 | ₹104.40 | -0.57% | |
| ₹98.80 | ₹140.35 | ₹98.80 | ₹131.10 | +32.69% | |
| ₹112.00 | ₹112.00 | ₹94.00 | ₹98.90 | -11.70% | |
| ₹87.00 | ₹112.00 | ₹84.00 | ₹110.10 | +26.55% | |
| ₹88.00 | ₹96.00 | ₹85.85 | ₹87.00 | -1.14% | |
| ₹92.15 | ₹95.00 | ₹84.50 | ₹89.25 | -3.15% | |
| ₹98.50 | ₹101.75 | ₹92.00 | ₹95.00 | -3.55% | |
| ₹100.95 | ₹104.35 | ₹95.10 | ₹98.70 | -2.23% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Microcap pharma play benefiting from India's growing pharmaceutical market, but liquidity and cash flow are major concerns.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Quest Laboratories announced financial results for the period ended December 31, 2025.
CORE STORY (THE REAL GAME)
- Indian pharma sector projected to reach $130 billion by 2030
- Shift towards chronic therapies driving value growth
- Promoter buying adds confidence
- New order wins
- Improved free cash flow
- Acquisition by a larger player
- Microcap SME = liquidity risk
- Negative free cash flow of ₹-22.48 Cr
- Dependence on generic drugs faces pricing pressure
Promoter increased stake by 0.57%, while FII decreased by 0.02% and DII decreased by 0.68%.
Indian pharmaceutical exports are growing, but face global pricing pressures.
No, Free Cash Flow 5Y: ₹-22.48 Cr
Quest Laboratories' future hinges on its ability to capitalize on the shift towards chronic therapies and expand its export reach. Improvement in cash flow is crucial for long-term sustainability.
Primary Thesis Risk
Inability to generate positive free cash flow will kill the thesis.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
QUEST LABORATORIES Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
QUEST LABORATORIES Fundamental Analysis & Valuation Benchmarking
Educational evaluation of QUESTLAB across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (16.82%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (18.41%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.30%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 9.79 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (47.94%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (29.79% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (86.82% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.08)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (10.79x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (66.78%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Revenue Contraction (-30.25%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Negative Free Cash Flow (₹-38.29 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.65%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
QUEST LABORATORIES vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare QUEST LABORATORIES with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
62.2/100 | ₹89.25₹89 | ₹146.99₹146.99 | 9.79Average 9.8 Average | 16.82%Good 16.82% Good | 18.41%Good 18.41% Good | 0.08Excellent 0.1 Excellent | 86.82%Excellent 86.82% Excellent | 29.79%Excellent 29.79% Excellent | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
QUEST LABORATORIES Quarterly Performance
Latest quarterly metrics for QUESTLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-30.25%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
47.94%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
29.79%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
86.82%
Compounded annual net profit growth over 5 years
QUEST LABORATORIES Technical Indicators
SMA 50, SMA 200, RSI and volume signals for QUESTLAB — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
QUEST LABORATORIES Financial Statements
Annual income statement, balance sheet and cash flow for QUEST LABORATORIES (QUESTLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for QUEST LABORATORIES
About QUESTLAB (QUEST LABORATORIES)
QUEST LABORATORIES (QUESTLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a cur...rent market capitalisation of ₹146.99 (Cr). QUEST LABORATORIES has delivered a Return on Equity (ROE) of 16.82% and a ROCE of 18.41%. The debt-to-equity ratio stands at 0.08, reflecting the company's capital structure. Investors tracking QUESTLAB share price can monitor key metrics including P/E ratio, promoter holding of 66.78%, and quarterly earnings growth.
Company Details
QUESTLAB Share Price: Frequently Asked Questions
What is the current share price of QUEST LABORATORIES?
QUEST LABORATORIES (QUESTLAB) trades at ₹89.25 on NSE. Market cap ₹146.99 (Cr). Educational data only.
What is the P/E ratio of QUEST LABORATORIES?
QUEST LABORATORIES has a P/E of 9.79x vs industry average 34.89x.
What is the Bull Run score for QUEST LABORATORIES?
QUEST LABORATORIES has a Bull Run score of 62.2/100 based on 25+ financial parameters.
Does QUEST LABORATORIES pay dividends?
QUEST LABORATORIES has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of QUEST LABORATORIES?
QUEST LABORATORIES has ROE of 16.82%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of QUEST LABORATORIES?
QUEST LABORATORIES has debt-to-equity of 0.08.
Is QUEST LABORATORIES a good investment?
Bull Run gives QUEST LABORATORIES a score of 62.2/100. This is not investment advice — consult a SEBI-registered advisor.